BidaskClub Upgrades Agenus (AGEN) to Hold

BidaskClub upgraded shares of Agenus (NASDAQ:AGEN) from a sell rating to a hold rating in a research report released on Saturday morning.

AGEN has been the topic of several other research reports. Zacks Investment Research downgraded Agenus from a buy rating to a hold rating in a research report on Monday, January 15th. ValuEngine downgraded Agenus from a sell rating to a strong sell rating in a research report on Friday, December 29th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. Agenus presently has a consensus rating of Hold and an average target price of $5.81.

Shares of Agenus (NASDAQ AGEN) opened at $4.35 on Friday. The stock has a market capitalization of $435.80, a P/E ratio of -3.72 and a beta of 2.10. Agenus has a twelve month low of $3.20 and a twelve month high of $5.45. The company has a current ratio of 1.55, a quick ratio of 1.55 and a debt-to-equity ratio of -2.39.

In other news, insider Karen Valentine sold 8,358 shares of the business’s stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $3.46, for a total transaction of $28,918.68. Following the transaction, the insider now owns 109,879 shares of the company’s stock, valued at approximately $380,181.34. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last three months, insiders have sold 20,514 shares of company stock worth $70,978. Corporate insiders own 7.90% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AGEN. Artal Group S.A. increased its position in shares of Agenus by 25.0% during the 3rd quarter. Artal Group S.A. now owns 2,500,000 shares of the biotechnology company’s stock valued at $11,025,000 after purchasing an additional 500,000 shares during the last quarter. Vanguard Group Inc. grew its position in Agenus by 5.2% in the 2nd quarter. Vanguard Group Inc. now owns 3,530,585 shares of the biotechnology company’s stock valued at $13,805,000 after acquiring an additional 174,162 shares during the last quarter. Hudson Bay Capital Management LP grew its position in Agenus by 60.7% in the 4th quarter. Hudson Bay Capital Management LP now owns 450,000 shares of the biotechnology company’s stock valued at $1,467,000 after acquiring an additional 170,000 shares during the last quarter. RTW Investments LP grew its position in Agenus by 2.6% in the 4th quarter. RTW Investments LP now owns 4,329,816 shares of the biotechnology company’s stock valued at $14,115,000 after acquiring an additional 111,296 shares during the last quarter. Finally, Virtus Fund Advisers LLC bought a new position in Agenus in the 4th quarter valued at $320,000. 37.44% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This story was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another site, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The original version of this story can be read at https://www.dispatchtribunal.com/2018/02/20/bidaskclub-upgrades-agenus-agen-to-hold.html.

About Agenus

Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply